Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQB2618 plus Benmelstobart in Advanced Solid Tumors
NCT05645315Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Apr 2022
- Primary completion
- Dec 2023
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of TQB2618 in solid tumor (advanced stage), non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
TQB2618
03
Conditions
solid tumor (advanced stage)non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05645315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05645315.